
# IFN-gamma is Central to Both Immunogenic and Tolerogenic Properties of Dendritic Cells After IL-12 and GM-CSF Microsphere Treatment

Jamie Harden
SUNY Buffalo
School of Medicine and Biomedical
Science

#### Previous Data:


#### **Tumor**




## Background


- Dendritic Cells (DCs)
  - The most potent antigen presenting cell master regulator of the immune response
  - Can prime in animmunogenic ORtolerogenic fashion

How does GM-CSF and IL-12 microsphere treatment affect DCs?



# DC numbers increase in tumor and tumor draining lymph nodes after treatment







Absolute DC numbers in the tumor

Absolute DC numbers in the TDLN post-Rx


#### DCs post-treatment upregulate CCR7 and CD86

Gated on CD45+, CD11c+, MHCII+ (DCs)





# DCs become immunogenic after treatment, followed by tolerogenicity




What is the cause of the poor DC priming ability by Day 7 post-treatment?

#### IDO is upregulated in DCs post-treatment

Intracellular Staining for IDO









Isotype control primary antibody with secondary antibody:


Intracellular IDO staining of untreated TDLN sample:







#### IDO mediates post-treatment DC tolerogenicity

Addition of D1MT restores priming ability to D7Rx DC, but not pre-treatment DCs



Day 7 post-Rx
DC Priming






# Requires IFN-gamma


- Effector memory CD8+ T-cell activation
- Reduction in T-reg numbers
- NK cell activation
- De novo CD8+ T-cell priming in TDLN


Is IFN-gamma required for treatment mediated affects on DCs?

## IFN-gamma drives DC immunogenicity




### IFN-gamma drives DC regulation via IDO






Live/MHCII - PerCP subset/Q4: CD11c-APC+, B220 - PE-

# Addition of D1MT to microsphere treatment results in complete regression of tumors





Central Role of IFNγ-Indoleamine 2,3-Dioxygenase Axis in Regulation of Interleukin-12-Mediated Antitumor Immunity. Tao Gu et al. Cancer Res. 70(1) 129-38.

## Summary:

Intratumoral GM-CSF and IL-12 microsphere Rx

IFN-gamma

IFN-gamma

D0

- Low DC

numbers in

tumor and

-CCR7 and

-Poor *in vitro* 

priming ability

CD86 low

**TDLN** 

D2

- - -DC numbers increase in tumor followed by TDLN
  - -CCR7 upregulation
  - -CD86 upregulation
  - -Superior *in vitro* priming ability

-Upregulation of immunosuppressive IDO

D7

- -Loss of superior priming ability
- -Reversible by addition of D1MT

# Acknowledgements

